Key result
In 41 patients undergoing left main PCI with the BioMime Morph tapered sirolimus-eluting stent, there were 0 major adverse cardiovascular events during a median follow-up of 20 months.
Why the study?
Currently, no data is available on the clinical usefulness of tapered ultrathin stents in left main PCI.
Does a novel tapered sirolimus-eluting stent prevent major adverse cardiovascular events in patients undergoing left main to branch vessel PCI?
Observational (n=41)
No
Does a novel tapered sirolimus-eluting stent prevent major adverse cardiovascular events in patients undergoing left main to branch vessel PCI?
The use of a novel tapered sirolimus-eluting stent for left main PCI appears safe and feasible, with no major adverse cardiovascular events observed over a median 20-month follow-up in a small real-world cohort.
May support tapered SES feasibility in left main PCI; leaves open randomized confirmation of safety and efficacy.
OBJECTIVE: To assess the safety and efficacy of Novel tapered (BioMime™ Morph) sirolimus- eluting stent (SES) for left main PCI in a real-world scenario. BACKGROUND: Currently, no data is available on clinical usefulness of tapered ultrathin stents in left main PCI. METHODS: This was a prospective, non-randomised, single centre study carried out between February 2018 and May 2020 at a tertiary cardiac care centre in southern India. The study included patients treated with BioMime Morph tapered stent for distal de novo LMB lesion or ostial LAD/LCX lesions with significant size disparity between reference segments based on the eligibility criteria. Primary endpoint of the study was the cumulative incidence of major adverse cardiovascular events (MACE) composed of cardiac death, myocardial infarction, and clinically driven target-lesion revascularisation at follow-up. RESULTS: A total of 41 patients (average age of 54.83±9.81 years) were included in the study. Average SS-2 score was 23.17±5.42. Majority of the lesions (n=31; 75.61%) were of medina class (0.1.0). Provisional single stent strategy was adopted for treatment of LMB lesions. TIMI flow-3 was achieved in 40 patients (97.56%). Median clinical follow-up was 20 months (range 6-34 months). There was no periprocedural complication or MACE during follow-up. CONCLUSION: Tapered stents may be an acceptable alternative for LM intervention in an anatomical subset of patients with tapered vessels.
No takes yet. Share an insight, caveat, or question.
Raghu et al. (2021) conducted an observational in Left main coronary artery disease (n=41). BioMime Morph tapered sirolimus-eluting stent was evaluated on Cumulative incidence of major adverse cardiovascular events (MACE) composed of cardiac death, myocardial infarction, and clinically driven target-lesion revascularisation at follow-up. In 41 patients undergoing left main PCI with the BioMime Morph tapered sirolimus-eluting stent, there were 0 major adverse cardiovascular events during a median follow-up of 20 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: